A single-center retrospective study to determine clinical outcomes of Blinatumomab and Inotuzumab ozogamicin in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Latest Information Update: 15 Sep 2021
At a glance
- Drugs Blinatumomab (Primary) ; Inotuzumab ozogamicin (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 15 Sep 2021 New trial record